Development of novel 3D-QSAR combination approach for screening and optimizing B-Raf inhibitors in silico

Journal of Chemical Information and Modeling

Volumn 51, Issue 2, 2011, Pages 398-407

  Shih, Kuei Chung ^a   Lin, Chun Yuan ^b   Zhou, Jiayi ^a   Chi, Hsiao Chieh ^b   Chen, Ting Shou ^c   Wang, Chun Chung ^c   Tseng, Hsiang Wen ^c   Tang, Chuan Yi ^a,d  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

^b CHANG GUNG UNIVERSITY   (Taiwan)

^c INDUSTRIAL TECHNOLOGY RESEARCH INSTITUTE   (Taiwan)

^d PROVIDENCE UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO ACIDS; CELL DEATH; CELL PROLIFERATION; LEAST SQUARES APPROXIMATIONS; ONCOLOGY;

CANCER THERAPY; CELL DIVISIONS; COMBINATION APPROACHES; COMBINATION MODELS; COMMON FACTORS; PARTIAL LEAST SQUARE (PLS); PHARMACOPHORES; VALIDATION RESULTS;

COMPUTATIONAL CHEMISTRY;

B RAF KINASE; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING SITE; BIOLOGY; CHEMICAL STRUCTURE; CHEMISTRY; DRUG ANTAGONISM; DRUG DESIGN; DRUG SCREENING; FACTUAL DATABASE; METABOLISM; METHODOLOGY; PROTEIN CONFORMATION; QUANTITATIVE STRUCTURE ACTIVITY RELATION; REGRESSION ANALYSIS; REPRODUCIBILITY;

BINDING SITES; COMPUTATIONAL BIOLOGY; DATABASES, FACTUAL; DRUG DESIGN; DRUG EVALUATION, PRECLINICAL; LEAST-SQUARES ANALYSIS; MODELS, MOLECULAR; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; QUANTITATIVE STRUCTURE-ACTIVITY RELATIONSHIP; REPRODUCIBILITY OF RESULTS;

EID: 79952139691     PISSN: 15499596     EISSN: 1549960X     Source Type: Journal    
DOI: 10.1021/ci100351s     Document Type: Article

References (36)

1. Mercer, K. E.; Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational target Biochim. Biophys. Acta, Rev. Cancer 2003, 1653, 25-40 (Pubitemid 36627818)
2. Garnett, M. J.; Marais, R. Guilty as charged: B-RAF is a human oncogene Cancer Cell 2004, 6, 313-9 (Pubitemid 39361432)
3. Karasarides, M.; Chiloeches, A.; Hayward, R.; Niculescu-Duvaz, D.; Scanlon, I.; Friedlos, F.; Ogilvie, L.; Hedley, D.; Martin, J.; Marshall, C. J.; Springer, C. J.; Marais, R. B-RAF is a therapeutic target in melanoma Oncogene 2004, 23, 6292-8 (Pubitemid 39215299)
4. Montagut, C.; Settleman, J. Targeting the RAF-MEK-ERK pathway in cancer therapy Cancer Lett. 2009, 283, 125-34
5. Yang, H.; Higgins, B.; Kolinsky, K.; Packman, K.; Go, Z.; Iyer, R.; Kolis, S.; Zhao, S.; Lee, R.; Grippo, J. F.; Schostack, K.; Simcox, M. E.; Heimbrook, D.; Bollag, G.; Su, F. RG7204 (PLX4032), a selective BRAFV600E inhibitor, displays potent antitumor activity in preclinical melanoma models Cancer Res. 2010, 70, 5518-27
6. Roberts, P. J.; Der, C. J. Targeting the Raf-MEK-ERK mitogen-activated protein kinase cascade for the treatment of cancer Oncogene 2007, 26, 3291-310 (Pubitemid 46763022)
7. Rubinstein, J. C.; Sznol, M.; Pavlick, A. C.; Ariyan, S.; Cheng, E.; Bacchiocchi, A.; Kluger, H. M.; Narayan, D.; Halaban, R. Incidence of the V600K mutation among melanoma patients with BRAF mutations, and potential therapeutic response to the specific BRAF inhibitor PLX4032 J. Transl. Med. 2010, 8, 67
8. Schwartz, G. K.; Yazji, S.; Mendelson, D. S.; Dickson, M. A.; Johnston, S. H.; Wang, E. W.; Shannon, P.; Pace, L.; Gordon, M. S. A phase 1 study of XL281, a potent and selective inhibitor of RAF kinases, administered orally to patients (pts) with advanced solid tumors EJC Suppl. 2008, 6, 120-120
9. Al-Masri, I. M.; Mohammad, M. K.; Taha, M. O. Discovery of DPP IV inhibitors by pharmacophore modeling and QSAR analysis followed by in silico screening ChemMedChem 2008, 3, 1763-79
10. Chopra, M.; Gupta, R.; Gupta, S.; Saluja, D. Molecular modeling study on chemically diverse series of cyclooxygenase-2 selective inhibitors: generation of predictive pharmacophore model using catalyst J. Mol. Model. 2008, 14, 1087-99
11. Kansal, N.; Silakari, O.; Ravikumar, M. Three dimensional pharmacophore modelling for c-Kit receptor tyrosine kinase inhibitors Eur. J. Med. Chem. 2010, 45, 393-404
12. Lauria, A.; Ippolito, M.; Fazzari, M.; Tutone, M.; Di Blasi, F.; Mingoia, F.; Almerico, A. M. IKK-beta inhibitors: An analysis of drug-receptor interaction by using Molecular Docking and Pharmacophore 3D-QSAR approaches J. Mol. Graphics Modell. 2010, 29, 72-81
13. Abu Hammad, A. M.; Taha, M. O. Pharmacophore modeling, quantitative structure-activity relationship analysis, and shape-complemented in silico screening allow access to novel influenza neuraminidase inhibitors J. Chem. Inf. Model. 2009, 49, 978-96
14. Markt, P.; Feldmann, C.; Rollinger, J. M.; Raduner, S.; Schuster, D.; Kirchmair, J.; Distinto, S.; Spitzer, G. M.; Wolber, G.; Laggner, C.; Altmann, K. H.; Langer, T.; Gertsch, J. Discovery of novel CB2 receptor ligands by a pharmacophore-based virtual screening workflow J. Med. Chem. 2009, 52, 369-78
15. Taha, M. O.; Dahabiyeh, L. A.; Bustanji, Y.; Zalloum, H.; Saleh, S. Combining ligand-based pharmacophore modeling, quantitative structure-activity relationship analysis and in silico screening for the discovery of new potent hormone sensitive lipase inhibitors J. Med. Chem. 2008, 51, 6478-94
16. Cramer, R. D., III; Patterson, D. E.; Bunce, J. D. Comparative molecular field analysis (CoMFA). 1. Effect of shape on binding of steroids to carrier proteins J. Am. Chem. Soc. 1988, 110, 5959-67
17. Jiang, Y. K. Molecular docking and 3D-QSAR studies on beta-phenylalanine derivatives as dipeptidyl peptidase IV inhibitors J. Mol. Model. 2010, 16, 1239-49
18. Khedkar, V. M.; Ambre, P. K.; Verma, J.; Shaikh, M. S.; Pissurlenkar, R. R.; Coutinho, E. C. Molecular docking and 3D-QSAR studies of HIV-1 protease inhibitors J. Mol. Model. 2010, 16, 1251-68
19. Lei, B. L.; Du, J.; Li, S. Y.; Liu, H. X.; Ren, Y. Y.; Yao, X. J. Comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) of thiazolone derivatives as hepatitis C virus NS5B polymerase allosteric inhibitors J. Comput.-Aided Mol. Des. 2008, 22, 711-725
20. Klebe, G.; Abraham, U.; Mietzner, T. Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity J. Med. Chem. 1994, 37, 4130-46 (Pubitemid 24379702)
21. Lu, P.; Wei, X.; Zhang, R. CoMFA and CoMSIA studies on HIV-1 attachment inhibitors Eur. J. Med. Chem. 2010, 45, 1792-8
22. Zeng, J.; Liu, G. X.; Tang, Y.; Jiang, H. L. 3D-QSAR studies on fluoropyrrolidine amides as dipeptidyl peptidase IV inhibitors by CoMFA and CoMSIA J. Mol. Model. 2007, 13, 993-1000 (Pubitemid 47202392)
23. Murumkar, P. R.; Zambre, V. P.; Yadav, M. R. Development of predictive pharmacophore model for in silico screening, and 3D QSAR CoMFA and CoMSIA studies for lead optimization, for designing of potent tumor necrosis factor alpha converting enzyme inhibitors J. Comput.-Aided Mol. Des. 2010, 24, 143-56
24. Pasha, F. A.; Muddassar, M.; Neaz, M. M.; Cho, S. J. Pharmacophore and docking-based combined in-silico study of KDR inhibitors J. Mol. Graphics Modell. 2009, 28, 54-61
25. Chen, Y.; Li, H.; Tang, W.; Zhu, C.; Jiang, Y.; Zou, J.; Yu, Q.; You, Q. 3D-QSAR studies of HDACs inhibitors using pharmacophore-based alignment Eur. J. Med. Chem. 2009, 44, 2868-76
26. Lu, X. Y.; Chen, Y. D.; You, Q. D. 3D-QSAR studies of arylcarboxamides with inhibitory activity on InhA using pharmacophore-based alignment Chem. Biol. Drug Des. 2010, 75, 195-203
27. Chaudhaery, S. S.; Roy, K. K.; Saxena, A. K. Consensus superiority of the pharmacophore-based alignment, over maximum common substructure (MCS): 3D-QSAR studies on carbamates as acetylcholinesterase inhibitors J. Chem. Inf. Model. 2009, 49, 1590-601
28. Palomer, A.; Pascual, J.; Cabre, F.; Garcia, M. L.; Mauleon, D. Derivation of pharmacophore and CoMFA models for leukotriene D(4) receptor antagonists of the quinolinyl(bridged)aryl series J. Med. Chem. 2000, 43, 392-400 (Pubitemid 30102079)
29. Boppana, K.; Dubey, P. K.; Jagarlapudi, S. A.; Vadivelan, S.; Rambabu, G. Knowledge based identification of MAO-B selective inhibitors using pharmacophore and structure based virtual screening models Eur. J. Med. Chem. 2009, 44, 3584-90
30. Osman, F. G. D.; Henry, R. Metric for analyzing hit lists and pharmacophores. In. Phamacophore Perception, Development, and Use in Drug Design; Guner., O. F., Ed.; International University Line: La Jolla, CA, 2000; pp 193 - 210.
31. Ravikumar, M.; Pavan, S.; Bairy, S.; Pramod, A. B.; Sumakanth, M.; Kishore, M.; Sumithra, T. Virtual screening of cathepsin k inhibitors using docking and pharmacophore models Chem. Biol. Drug Des. 2008, 72, 79-90 (Pubitemid 351852773)
32. Vadivelan, S.; Sinha, B. N.; Irudayam, S. J.; Jagarlapudi, S. A. Virtual screening studies to design potent CDK2-cyclin A inhibitors J. Chem. Inf. Model. 2007, 47, 1526-35 (Pubitemid 47210055)
33. Liu, T.; Lin, Y.; Wen, X.; Jorissen, R. N.; Gilson, M. K. BindingDB: a web-accessible database of experimentally determined protein-ligand binding affinities Nucleic Acids Res. 2007, 35, D198-201
34. Sprague, P. W. Automated chemical hypothesis generation and database searching with Catalyst(R) Perspect. Drug Discovery Des. 1995, 3, 1-20
35. Brooks, B. R.; Bruccoleri, R. E.; Olafson, B. D.; States, D. J.; Swaminathan, S.; Karplus, M. Charmm-a Program for Macromolecular Energy, Minimization, and Dynamics Calculations J. Comput. Chem. 1983, 4, 187-217
36. Discovery Studio, version 2.1; Accelrys: San Diego, CA, 2008.